Analysts Issue Forecasts for VYGR FY2025 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for Voyager Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will earn ($2.20) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $5.73 target price on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.29. The company had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the previous year, the business posted ($0.59) EPS.

A number of other equities analysts have also weighed in on the company. Leerink Partners initiated coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price on the stock. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Citigroup started coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective for the company. Canaccord Genuity Group restated a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. Finally, Wedbush began coverage on Voyager Therapeutics in a research note on Friday, November 29th. They issued an “outperform” rating and a $11.00 price objective for the company. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $15.97.

Voyager Therapeutics Stock Performance

VYGR stock opened at $5.43 on Wednesday. The stock’s 50 day simple moving average is $5.82 and its 200 day simple moving average is $6.67. The company has a market cap of $296.64 million, a P/E ratio of 7.65 and a beta of 0.93. Voyager Therapeutics has a fifty-two week low of $4.99 and a fifty-two week high of $10.66.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 10,778 shares of company stock worth $58,548 in the last 90 days. Insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Armistice Capital LLC lifted its position in shares of Voyager Therapeutics by 11.3% during the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after buying an additional 528,000 shares during the last quarter. Great Point Partners LLC bought a new stake in Voyager Therapeutics in the 2nd quarter valued at about $12,668,000. Geode Capital Management LLC lifted its holdings in Voyager Therapeutics by 0.6% during the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock valued at $6,316,000 after purchasing an additional 6,740 shares during the last quarter. Erste Asset Management GmbH bought a new position in Voyager Therapeutics during the third quarter worth about $6,192,000. Finally, American Century Companies Inc. increased its stake in shares of Voyager Therapeutics by 32.4% in the second quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock worth $8,063,000 after purchasing an additional 249,659 shares in the last quarter. Institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.